Chemothetrapy induced nausea in solid cancer patients. Nausea and vomiting
Conditions
Interventions
Intervention 1: Intervention group: Injection of placebo 6 hours before first cycle of chemotherapy beside other usual Antiemetics and evaluation of early and delayed nausea in all patients. Intervent
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: patients with solid cancer who are under chemotherapy
Exclusion criteria
Exclusion criteria: Known hypersensitivity or allergic reaction to Vitamin B6 or Vitamin C Any change in chemotherapy regimen between the first and second cycles Severe renal impairment (eGFR < 30 mL/min/1.73 m²) or history of recurrent nephrolithiasis Severe hepatic impairment Concurrent use of non-standard antiemetic regimens or high-dose vitamin supplements Pregnancy or breastfeeding Symptomatic brain metastases or other causes of nausea and vomiting unrelated to chemotherapy Uncontrolled nausea and vomiting prior to initiation of the study (baseline instability)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of chemotherapy induced nausea on the basis of MAT Questionnaire. Timepoint: 24 hours and 72 hours after intervention. Method of measurement: by the use of The Multinational Association of Supportive Care in Cancer (MASCC) Antiemesis Tool (MAT). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact??? ??? ??????????
??????? ?????????? ?????
Outcome results
None listed